Frontotemporal Dementia Drug Discovery Program.
This year’s recipients are engaged in the kind of research that provides both caregivers and patients the optimism they have to face the challenges of coping with FTD. We are proud to be partnering with the ADDF to support their function and the hope it brings to those suffering from this terrible disease. .. ADDF, AFTD announce recipients of Frontotemporal Dementia Drug Discovery Program award The Alzheimer’s Medication Discovery Base and the Association for Frontotemporal Dementias announced today the recipients of their third annual research award, Frontotemporal Dementia Drug Discovery Program. The ADDF/AFTD plan awarded $300,000 to three academic scientists on the cutting edge of study for FTD. The award winners are: Philip Van Damme, MD, Ph.D., VIB, Leuven University ; Einar M.Early substance abuse intervention techniques reduce individual morbidity and mortality and decrease overall costs to society. POCTs are tools which achieve a stability between preventing substance abuse and diversion and keeping proper levels of pain control for patients. In 2007, I founded Millennium Laboratories to play a broader role in stemming the tide of prescription drug abuse, addiction and diversion. If POCTs aren’t utilized by doctors who prescribe pain medications, many abusers, illicit medication users, and medication diverters will go undetected.